If you liked this article you might like

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
Momentum Is Fading
Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views
Biotechs Catching Their Breath: Cramer's 'Off The Charts'